EFFICACY AND SAFETY OUTCOMES OF DIPEPTIDYL PEPTIDASE 4-INHIBITORS AND SULFONYLUREAS IN TREATMENT OF TYPE II DIABETES MELLITUS

Publication date: 9 april 2018

A joint report of Aston Health and the Endocrinology Research Centre, Ministry of Health of Russia, on the meta-analysis of comparative clinical effectiveness and safety of the dipeptidyl peptidase 4-inhibitors and sulfonylureas for the treatment of type II diabetes mellitus was presented at the VIII all-Russian diabetes Congress with international participation "Diabetes mellitus is the pandemia of the XXI century".

As part of the work, 4 studies were analyzed with the participation of 10 288 patients with type II diabetes: 5 322 patients on DPP4-inhibitors, 890 - on SU therapy, 4 044 – on basic therapy of DM (including SU), as well as 32 patients on other forms of type II diabetes therapy. All studies have shown a high degree of satisfaction with taking DPP4-inhibitors by patients which is directly associated with a high level of patient compliance when combined with a low incidence of adverse events,
Meta-analysis data indicates the wide implementation in practice of DPP4-inhibitors due to their high efficacy and safety comparable to standard SU-therapy. It would be appropriate, in this respect, to further study the economic aspects’ impact and the financial loading of compared antidiabetic drugs on the Health budget of the Russian Federation.

Authors: Galstyan G. R., Demura S. A., Masienko M. S., Bukharov K. G.